Should You Be Worried About Pfizer Stock?
Pfizer (PFE) stock has returned 17.5% over the past three months, easily outpacing the 3.7% return for the S&P 500. The board also just declared its 352nd quarterly dividend in a row. That reliable payout may be why many investors hold the shares, yet on Pfizer’s latest earnings call, management was asked what it would take to cut that dividend. So what is Pfizer’s management preparing for?
Pfizer Faces Several Years Of Drugs Losing Exclusivity
Pfizer executives are preparing for some of the company’s drugs to lose exclusivity, lifting the protection that keeps rivals from selling the same medicine. During the fiscal Q2 2026 call on August 4, 2026, management discussed how these impending losses will impact the business over the next few years, describing the stretch as a transition period.
The company is navigating this transition with a cautious approach to debt. Pfizer ended the quarter with its leverage, a measure of its debt load, at 2.7 times. Executives expect it to stay around that level or go modestly higher as the company works through the transition. When asked on the same call about a cut, management said it could maintain the dividend even in the most stretched scenarios it runs.
Pfizer’s Revenue Is Almost All Biopharma
Pfizer has almost no other business to lean on outside of its primary drug segment. Biopharma generated 98% of the company’s fiscal 2025 revenue. The unit posted sales of $61.2 billion that year, sitting 1.9% lower than the year before.
Management raised its 2026 revenue guidance on the August 4 call, projecting between $60.5 billion and $62.5 billion. However, even the very top of that new range falls short of the $62.6 billion Pfizer reported in total for fiscal 2025.
The products that could eventually make up the difference still represent a minority of sales. Pfizer’s recently launched and acquired products brought in just $3.2 billion in the second quarter of 2026, out of total revenue of $15 billion. While those products grew 18% operationally from a year earlier, management noted that this growth rate was tempered by one-time items recorded in the second quarter of 2025.
The current share price appears to assume some of this already. Pfizer trades at 2.5 times sales, compared to 3.1 for the S&P 500. Over the past ten years, Pfizer’s own multiple has ranged from 2.2 to 6.4. Yet after its recent run, the stock sits only 3.5% below its 52-week high, which may leave it less room for a disappointment.
Can Pfizer Build Replacements In Time?
Based on the company’s own timetable, the looming threat looks slow rather than urgent. The upcoming exclusivity losses will play out over the next few years, and management ultimately aims for risk-adjusted high single-digit annual revenue growth from the end of 2028 through 2033. Pfizer is also targeting a first approval in 2028 for berobenatide, its obesity drug candidate. In the meantime, the company is actively cutting costs and expects about $9.7 billion of net savings through 2029.
Available capital for deals is relatively tight. Pfizer’s debt currently equals 39.6% of its market value, well above the 21.4% for the S&P 500. Management explicitly pegged its remaining capacity for business development deals at about $6 billion. The quarterly dividend absorbs significant cash as well: Pfizer paid $4.9 billion in dividends during the first half of 2026, which is close to the $5.5 billion it invested in R&D over the same period.
The next marker is the first readout from a trial of one of Pfizer’s drug candidates. Based on the current event rate, management expects that data to arrive in the fourth quarter of 2026. A positive result would move Pfizer closer to another new drug to set against the ones losing exclusivity.
How To Act On PFE?
Now you know PFE better. And that’s our purpose: to make you informed before you invest your money. However, making a bet on a single stock carries its own risks.
There is a smarter choice. Since its inception, the Trefis High Quality (HQ) Portfolio has beaten the benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking.
If you’d rather act on PFE itself:
| Play Offense | Play Defense |
|---|---|
| Learn More About PFE & Invest | Save Taxes On Capital Gain |
| Earn From PFE Cash Secured Puts | Covered Call Against PFE |